Marry M. van den Heuvel‐Eibrink
Papers
1
Total Citations
6
H-Index
1
About
Dr. Marry M. van den Heuvel‐Eibrink is a leading researcher at the intersection of pediatric oncology, endocrinology, and environmental health. Her work primarily focuses on understanding the long-term health outcomes of childhood cancer survivors, particularly the endocrine and metabolic complications arising from treatment. A major contribution is her pioneering research on the role of genetic and epigenetic factors in determining susceptibility to treatment-related toxicities, such as ototoxicity and nephrotoxicity, which has directly informed clinical guidelines for safer chemotherapy administration. With over 400 publications and a cumulative citation count exceeding 15,000, her impact is profound. Notably, she has led landmark studies on growth hormone deficiency and bone mineral density in survivors, and her work on cisplatin-induced hearing loss has been instrumental in developing protective strategies. Her achievements include serving as a key investigator in the International Late Effects of Childhood Cancer Guideline Harmonization Group, shaping global standards for survivor care. Dr. van den Heuvel‐Eibrink’s research continues to bridge the gap between survival and quality of life, offering hope and evidence-based solutions for children and families navigating cancer treatment.
Research Focus
Key Achievements
Top Papers
- 1